Harbour Capital Advisors Lowers stake in Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) : Harbour Capital Advisors reduced its stake in Johnson & Johnson by 0.92% during the most recent quarter end. The investment management company now holds a total of 18,876 shares of Johnson & Johnson which is valued at $2,232,276 after selling 175 shares in Johnson & Johnson , the firm said in a disclosure report filed with the SEC on Oct 13, 2016.Johnson & Johnson makes up approximately 1.22% of Harbour Capital Advisors’s portfolio.

Other Hedge Funds, Including , Marshwinds Advisory Co reduced its stake in JNJ by selling 139 shares or 0.71% in the most recent quarter. The Hedge Fund company now holds 19,368 shares of JNJ which is valued at $2,290,460. Johnson & Johnson makes up approx 1.15% of Marshwinds Advisory Co’s portfolio.Legal General Group Plc boosted its stake in JNJ in the latest quarter, The investment management firm added 55,306 additional shares and now holds a total of 13,750,590 shares of Johnson & Johnson which is valued at $1,617,619,408. Johnson & Johnson makes up approx 1.67% of Legal General Group Plc’s portfolio.Catawba Capital Management Va reduced its stake in JNJ by selling 100 shares or 0.17% in the most recent quarter. The Hedge Fund company now holds 57,122 shares of JNJ which is valued at $6,811,227. Johnson & Johnson makes up approx 1.64% of Catawba Capital Management Va’s portfolio.Beacon Financial Group reduced its stake in JNJ by selling 9,492 shares or 9.98% in the most recent quarter. The Hedge Fund company now holds 85,665 shares of JNJ which is valued at $10,209,555. Johnson & Johnson makes up approx 2.15% of Beacon Financial Group’s portfolio.

Johnson & Johnson closed down -2.16 points or -1.80% at $117.64 with 63,94,159 shares getting traded on Tuesday. Post opening the session at $119.41, the shares hit an intraday low of $117.06 and an intraday high of $119.63 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Johnson & Johnson reported $1.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 19, 2016. Analyst had a consensus of $1.68. The company had revenue of $18482.00 million for the quarter, compared to analysts expectations of $17985.80 million. The company’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.71 EPS.

Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by UBS on Jul 20, 2016 to “Buy”, Firm has raised the Price Target to $ 137 from a previous price target of $126 .Company shares were Reiterated by RBC Capital Mkts on Jul 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 133 from a previous price target of $125 .

Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Company’s research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Johnson & Johnson - Is it time to Sell?

Top Brokerage Firms are advising their investors on Johnson & Johnson. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.